Sulfonylurea has 32 known drug interactions based on U.S. FDA drug labeling data. 17 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Alogliptin And Metformin Hydrochloride, Alogliptin And Pioglitazone, Dapagliflozin. Patients taking Sulfonylurea should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 32
- Major
- 17
- Moderate
- 15
Major (17)
- Sulfonylurea + Alogliptin And Metformin Hydrochloride— Coadministration may increase risk of hypoglycemia, potentially requiring lower doses of the insulin secretagogue.
- Sulfonylurea + Alogliptin And Pioglitazone— Coadministration may require lower sulfonylurea dosages to reduce risk of hypoglycemia.
- Sulfonylurea + Dapagliflozin— Risk of hypoglycemia may be increased when dapagliflozin is used concomitantly with sulfonylurea insulin secretagogues. …
- Sulfonylurea + Dapagliflozin And Metformin Hydrochloride— Insulin secretagogue that increases hypoglycemia risk when combined with XIGDUO XR; may require lower doses.
- Sulfonylurea + Dapagliflozin And Saxagliptin— Increased risk of hypoglycemia when used with dapagliflozin and saxagliptin. May require lower insulin secretagogue dose…
- Sulfonylurea + Empagliflozin— Risk of hypoglycemia is increased when combined with empagliflozin; lower sulfonylurea doses may be needed.
- Sulfonylurea + Empagliflozin And Linagliptin— Risk of hypoglycemia is increased when GLYXAMBI is combined with sulfonylureas (insulin secretagogues). May require lowe…
- Sulfonylurea + Empagliflozin, Linagliptin, Metformin Hydrochloride— Concomitant use increases hypoglycemia risk; sulfonylurea dosage reduction may be needed.
- Sulfonylurea + Empagliflozin, Metformin Hydrochloride— Insulin secretagogue that increases hypoglycemia risk when combined; lower dosages may be required.
- Sulfonylurea + Linagliptin— Insulin secretagogue that increases hypoglycemia risk when combined with linagliptin. Lower dosages of sulfonylurea may …
- Sulfonylurea + Linagliptin And Metformin Hydrochloride— Insulin secretagogues increase hypoglycemia risk when combined with linagliptin and metformin. Sulfonylurea dosage may r…
- Sulfonylurea + Liraglutide— Liraglutide stimulates insulin release and increases risk of hypoglycemia, including severe hypoglycemia, when combined …
- Sulfonylurea + Metformin Hydrochloride— Insulin secretagogue that when combined with metformin may increase risk of hypoglycemia.
- Sulfonylurea + Methotrexate— Highly protein-bound drug that may increase methotrexate plasma concentrations, increasing risk of severe adverse reacti…
- Sulfonylurea + Pioglitazole And Metformin Hydrochloride— Insulin secretagogue coadministration increases hypoglycemia risk and may require dose reduction.
- Sulfonylurea + Semaglutide— Increased risk of hypoglycemia, including severe hypoglycemia. Consider reducing sulfonylurea dose when initiating semag…
- Sulfonylurea + Sitagliptin And Metformin Hydrochloride— Insulin secretagogue that increases hypoglycemia risk when combined with ZITUVIMET XR; may require dose reduction.
Moderate (15)
- Sulfonylurea + Alogliptin— Coadministration may increase hypoglycemia risk. Lower dosages of sulfonylurea may be required when used with alogliptin…
- Sulfonylurea + Canagliflozin And Metformin Hydrochloride— Insulin secretagogue that increases hypoglycemia risk when used with canagliflozin and metformin; dosage may need reduct…
- Sulfonylurea + Empagliflozin And Metformin Hydrochloride— Concomitant use increases hypoglycemia risk; sulfonylurea dosage may require reduction.
- Sulfonylurea + Metformin— Insulin secretagogue that increases hypoglycemia risk when coadministered with metformin.
- Sulfonylurea + Metformin Er 500 Mg— Insulin secretagogue that with metformin may increase risk of hypoglycemia. Patient may require lower doses of insulin s…
- Sulfonylurea + Metformin Hydrochloride Extended-Release Tablets— Insulin secretagogue that increases hypoglycemia risk when combined with metformin; may require dose adjustment.
- Sulfonylurea + Metformin Hydrochloride Tablet— Insulin secretagogue that when combined with metformin may increase risk of hypoglycemia.
- Sulfonylurea + Orforglipron— When initiating FOUNDAYO, consider reducing the dose of concomitantly administered sulfonylureas due to potential additi…
- Sulfonylurea + Porfimer Sodium— Concomitant use may increase the risk of photosensitivity reaction. Avoid concomitant use with other photosensitizing ag…
- Sulfonylurea + Salsalate— Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.
- Sulfonylurea + Sitagliptin— Coadministration may require lower doses of sulfonylurea to reduce the risk of hypoglycemia.
- Sulfonylurea + Sitagliptin Hydrochloride Oral— Coadministration may require lower dosages of sulfonylurea to reduce the risk of hypoglycemia.
- Sulfonylurea + Sitagliptin Phosphate— Coadministration with sitagliptin may require lower doses of sulfonylurea to reduce the risk of hypoglycemia.
- Sulfonylurea + Sulfadiazine— Potentiation of the action of sulfonylurea hypoglycemic agents may be noted, possibly due to displacement from albumin o…
- Sulfonylurea + Verteporfin For Injection— Other photosensitizing agents that could increase the potential for skin photosensitivity reactions.